ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib
Westport, CT, May 20, 2020 (GLOBE NEWSWIRE) -- Funding completed in subsidiary without dilution to BioSig common stock Phase II human trials for merimepodib, a broad-spectrum oral anti-viral treatment of adult hospitalized patients with COVID-19, are …